Bionano Genomics Inc. (BNGO)
Bionano Genomics Statistics
Share Statistics
Bionano Genomics has 2.73M shares outstanding. The number of shares has increased by -96.05% in one year.
| Shares Outstanding | 2.73M |
| Shares Change (YoY) | -96.05% |
| Shares Change (QoQ) | -97.32% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 3M |
| Failed to Deliver (FTD) Shares | 5.9K |
| FTD / Avg. Volume | 2.92% |
Short Selling Information
The latest short interest is 506.72K, so 16.85% of the outstanding shares have been sold short.
| Short Interest | 506.72K |
| Short % of Shares Out | 16.85% |
| Short % of Float | 16.91% |
| Short Ratio (days to cover) | 4.31 |
Valuation Ratios
The PE ratio is -0.29 and the forward PE ratio is -0.53. Bionano Genomics's PEG ratio is 0.
| PE Ratio | -0.29 |
| Forward PE | -0.53 |
| PS Ratio | 1.05 |
| Forward PS | 0.1 |
| PB Ratio | 0.91 |
| P/FCF Ratio | -0.47 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bionano Genomics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.06, with a Debt / Equity ratio of 0.77.
| Current Ratio | 1.06 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | -0.28 |
| Debt / FCF | -0.4 |
| Interest Coverage | -359.8 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $314.04K |
| Profits Per Employee | $-1.14M |
| Employee Count | 98 |
| Asset Turnover | 0.4 |
| Inventory Turnover | 2.73 |
Taxes
| Income Tax | 33K |
| Effective Tax Rate | -0.03% |
Stock Price Statistics
The stock price has increased by -91.33% in the last 52 weeks. The beta is 2.09, so Bionano Genomics's price volatility has been higher than the market average.
| Beta | 2.09 |
| 52-Week Price Change | -91.33% |
| 50-Day Moving Average | 4.15 |
| 200-Day Moving Average | 17.79 |
| Relative Strength Index (RSI) | 58.13 |
| Average Volume (20 Days) | 202.33K |
Income Statement
In the last 12 months, Bionano Genomics had revenue of 30.78M and earned -112.02M in profits. Earnings per share was -60.05.
| Revenue | 30.78M |
| Gross Profit | 380K |
| Operating Income | -103.98M |
| Net Income | -112.02M |
| EBITDA | -97.47M |
| EBIT | -111.69M |
| Earnings Per Share (EPS) | -60.05 |
Balance Sheet
The company has 9.17M in cash and 27.3M in debt, giving a net cash position of -18.12M.
| Cash & Cash Equivalents | 9.17M |
| Total Debt | 27.3M |
| Net Cash | -18.12M |
| Retained Earnings | -693.23M |
| Total Assets | 76.67M |
| Working Capital | 2.15M |
Cash Flow
In the last 12 months, operating cash flow was -68.92M and capital expenditures -103K, giving a free cash flow of -69.03M.
| Operating Cash Flow | -68.92M |
| Capital Expenditures | -103K |
| Free Cash Flow | -69.03M |
| FCF Per Share | -37 |
Margins
Gross margin is 1.23%, with operating and profit margins of -337.87% and -363.98%.
| Gross Margin | 1.23% |
| Operating Margin | -337.87% |
| Pretax Margin | -363.87% |
| Profit Margin | -363.98% |
| EBITDA Margin | -316.7% |
| EBIT Margin | -337.87% |
| FCF Margin | -224.28% |
Dividends & Yields
BNGO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BNGO is $7, which is 57.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $7 |
| Price Target Difference | 57.3% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Aug 7, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Aug 7, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -16.81 |
| Piotroski F-Score | 5 |